To help hospitals and health systems meet demand during the current surge in respiratory illnesses for fever-reducing products to treat pediatric patients and adults unable to swallow solid oral dosage forms, the Food and Drug Administration Friday released guidance for outsourcing facilities compounding certain ibuprofen oral suspension products.

“Although FDA is monitoring the global pharmaceutical supply chain and working, within its authorities, with manufacturers of approved ibuprofen oral suspension products, to bolster supply, temporary flexibility is needed to help ensure that treatment options are available to hospitals and health systems during this period of increased demand,” the guidance states. 

Related News Articles

Headline
The Department of Health and Human Services’ Office on Trafficking in Persons last week issued a request for information on forced labor in health care supply…
Perspective
We all know that the COVID-19 pandemic has exacerbated many longstanding challenges facing the health care field. One of the most alarming developments that is…
Headline
The Department of Defense, General Services Administration, and National Aeronautics and Space Administration today released a proposed rule intended to…
Headline
Non-traditional producers used additive manufacturing — also known as 3D printing — to deliver an estimated 38 million face shield parts, 12 million nasal…
Headline
The Food and Drug Administration identified 43 new drug and biological product shortages in 2020, down from 51 in 2019, and 86 ongoing shortages from prior…
Headline
The Department of Health and Human Services will establish a public-private consortium to increase U.S. production of essential medicines and active…